Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14900659 | 1.00 | LMNA (0.33) | LMNAPKMEPHX1ALDH1A1MIF | |
| SCHEMBL271716 | 1.00 | LMNA (0.33) | LMNAPKMEPHX1ALDH1A1MIF | |
| SCHEMBL16418041 | 0.82 | RAB9A (0.40) | LMNAPKMALDH1A1MIFTDP1 | |
| SCHEMBL14902832 | 0.79 | — | — | |
| SCHEMBL271148 | 0.78 | — | — | |
| SCHEMBL16449483 | 0.77 | — | — | |
| SCHEMBL11101825 | 0.75 | — | — | |
| SCHEMBL14900660 | 0.72 | ALDH1A1 (0.35) | ALDH1A1DDAH1 | |
| SCHEMBL14902790 | 0.71 | TDP1 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL204110 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112684028-B | Method for detecting purity of 2- (2-chloro-1-ethylene) hydrazide methyl formate | 中山奕安泰医药科技有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-112684028-A | Method for detecting purity of 2- (2-chloro-1-ethylene) hydrazide methyl formate | 中山奕安泰医药科技有限公司 | 2021-04-20 | — | — | CN | disclosed |
| US-7241798-B2 | NK1 antagonists | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050272800-A1 | NK1 antagonists | PFIZER INC | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272800-A1 | NK1 antagonists | TACR1, TACR2, TAC3 | LMNA 3937/4885PKM 877/4885EPHX1 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.